Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, OH.
Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, OH.
Surgery. 2019 Oct;166(4):496-502. doi: 10.1016/j.surg.2019.05.060. Epub 2019 Aug 29.
Familial adenomatous polyposis affects primarily the colon but can also involve other locations within the gastrointestinal tract, including the duodenum. The aim of this study was to describe a single center experience with pancreas-sparing duodenectomy for familial adenomatous polyposis and to compare outcomes with pancreatoduodenectomy performed for duodenal polyp disease.
A retrospective review of a prospectively maintained database identified patients who had undergone pancreas-sparing duodenectomy during the period 2001 to 2016. This population was matched 1:1 with a cohort of patients undergoing pancreatoduodenectomy for duodenal adenomas, both sporadic and familial, during the same time period. Baseline demographics and perioperative (short- and long-term) outcomes were compared.
A total of 88 patients were included; 44 in each group. The pancreas-sparing duodenectomy cohort was younger (52.6 vs 64.3 years; P < .001) and more patients had undergone prior colectomy (100% vs 32%; P < .001) or additional prior abdominal surgery (27% vs 9% (P < .001). Median operative times were greater for pancreatoduodenectomy (391 vs 460 min; P = .002). There was no difference in any of the early postoperative complications. There was 1 30-day mortality in the pancreatoduodenectomy group secondary to aspiration. Late acute pancreatitis was more common after pancreas-sparing duodenectomy (16% vs 0%; P = .012) and exocrine pancreatic insufficiency was more common after pancreatoduodenectomy (30% vs 11%; P = .034).
Pancreas-sparing duodenectomy is a reasonable option for duodenal cancer prophylaxis in familial adenomatous polyposis with high-risk features. The perioperative safety profile is comparable to pancreatoduodenectomy done for similar indications, and pancreas-sparing duodenectomy has a favorable long-term with a lesser incidence of exocrine impairment.
家族性腺瘤性息肉病主要影响结肠,但也可能涉及胃肠道的其他部位,包括十二指肠。本研究的目的是描述一家中心在家族性腺瘤性息肉病行保留胰腺的十二指肠切除术的经验,并将其与因十二指肠息肉病而行胰十二指肠切除术的结果进行比较。
通过回顾性分析前瞻性维护的数据库,确定了 2001 年至 2016 年间行保留胰腺的十二指肠切除术的患者。将这一人群与同期因散发性和家族性十二指肠腺瘤行胰十二指肠切除术的患者进行 1:1 匹配。比较了两组患者的基线人口统计学资料和围手术期(短期和长期)结果。
共纳入 88 例患者,每组 44 例。保留胰腺的十二指肠切除术组患者更年轻(52.6 岁 vs 64.3 岁;P <.001),且更多患者接受了先前的结肠切除术(100% vs 32%;P <.001)或其他先前的腹部手术(27% vs 9%;P <.001)。胰十二指肠切除术的中位手术时间更长(391 分钟 vs 460 分钟;P =.002)。两组患者的早期术后并发症无差异。胰十二指肠切除术组有 1 例患者术后 30 天因吸入性肺炎死亡。保留胰腺的十二指肠切除术后更常发生迟发性急性胰腺炎(16% vs 0%;P =.012),而胰十二指肠切除术后更常发生外分泌胰腺功能不全(30% vs 11%;P =.034)。
对于有高危特征的家族性腺瘤性息肉病,行保留胰腺的十二指肠切除术是预防十二指肠癌的合理选择。围手术期安全性与因类似适应证而行胰十二指肠切除术相当,且保留胰腺的十二指肠切除术具有良好的长期效果,外分泌功能障碍发生率较低。